Disposal of atrial natriuretic factor (ANF99-126) in patients with cirrhosis by Bendtsen, Flemming et al.
The Scandinavian Journal of 
Clinical & Laboratory 
Investigation 
EDITED BY 
THE S C A N D I N A V I A N SOCIETY 
FOR C L I N I C A L CHEMISTRY 
A N D C L I N I C A L PHYSIOLOGY 
M A N A G I N G E D I T O R 
O. Stokke 
E D I T O R S 
J. Hartiala 
J. H. Henriksen 
E. Hultman 
M . H0rder 
K. Liewendahl 
K. O. Pedersen 




E D I T O R I A L S E C R E T A R Y 
T. A. Hagve 
Scand. J. C l i n . L a b . I n v e s t . - V o l . 53 - 1 993 
BLACKWELL SCIENTIFIC PUBLICATIONS 
Published for 
Medisinsk Fysiologisk Forenings Foriag, Oslo by 
Blackwell Scientific Publications 
Osney Mead, Oxford OX2 OEL 
25 John Street, London WC1N 2BL 
23 Ainslie Place, Edinburgh E H 3 6AJ 
54 University Street, Carlton, Victoria 3053, Australia 
© 1993 Medisinsk Fysiologisk Forenings Foriag, Institute of 
Cinical Biochemistry, Rikshospitalet, N-0027 Oslo 1. 
Printed and bound in Great Britain 
by the Devonshire Press, Torquay 
Authorization to photocopy for internal or personal use or the 
internal or personal use of specific clients is granted by 
Medisinsk Fysiologisk Forenings Foriag for libraries and 
other users registered with the Copyright Clearance Center 
( C C C ) Transactional Reporting Service, provided that the 
base fee of SI0.00 per copy is paid directly to the C C C , 
27 Congress Street, Salem, M A 01970, USA. This consent 
does not extend to other kinds of copying, such as copying 
for general distribution, for advertising or promotional pur-
poses, for creating new collective works or for resale. Special 







Immunoassays for carcinoembryonic antigen: specificity and interferences: O. P. Bormer . . . . 1 
Original Articles 
Effect of allopurinol on myocardial recovery during reperfusion: H. Soncul, L . Gö'kgöz, 
S. Kalaycioglu, V. Sinei, M. Kaptanoglu & A. Ersöz 11 
Human cationic, pancreatic elastase in acute pancreatitis: H.-O. Hdkansson, A. Borgström & 
K. Ohlsson 17 
Effect of intravenous glucagon infusion on renal haemodynamics and renal tubular handling 
of sodium in healthy humans: S. Schwartz Serensen, E. Eiskjcer, H. ßrskov & E. Bjerre-
gaard Pedersen 25 
Value of serum alkaline phosphatase, aminotransferases, gamma-glutamyl transferase, leucine 
aminopeptidase, and bilirubin in the distinction between benign and malignant diseases 
causing jaundice and cholestasis: results from a prospective study; P. Pasanen, P. Pikkar-
ainen, E. Alhava, K. Partanen & I. Penttilä 35 
Comparative study of atrial peptides A N F (1-98) and A N F (99-126) as diagnostic markers 
of atrial distension in patients with cardiac disease: P. Mathisen, C. Hall & S. Simonsen 41 
Commutability of control materials in cholesterol measurement: C. Franzini & P. Luraschi. . 51 
Sodium-potassium pump activity in white blood cells from children with an increased risk of 
developing hypertension—The Odense Schoolchild Study: H. S. Hansen, J. R. Nielsen, 
K. E. Pedersen, T. Johansen, N. A. Klitgaard, N. Hyldebrandt & K. Froberg 57 
Central venous oxygen saturation during hypovalaemic shock in humans: P. Madsen, H. 
Iversen & N. H. Secher 67 
Improved electrophoretic method for the analysis of dystrophin in human muscle: H. Stibler, 
L . Edström & A.-M. Olsson 73 
Technical Note 
Automated procedure for measuring T B A R S for in vitro comparison of the effect of anti-
oxidants on tissues: L . Svensson, I. Börjesson, B. Kull & P. O. Sjöquist 83 
Letter to the Editor 
Coproporphyrin isomers in acute-intermittent porphyria: E. I. Minder 87 
No. 2 
Invited Review 
Release of atrial natriuretic factor: G. Christensen 91 
Review of a Scandinavian Thesis 
Contributions to the treatment of primary liver cancer. ^-Epidoxorubicin and cisplatin 
studied in hepatocarcinoma cell cultures and in partially hepatectomized rats: K. Sundby 
Hall 101 
Original Articles 
Inhibitors of the arachidonic acid metabolism attenuate the thyroliberin (TRH) stimulated 
prolactin production without modifying the production of inositolphosphates in G H 4 Q 
pituitary cells: T. Bjero, K. Englund, P.A. Torjesen & E. Haug I l l 
The contact system in human malignant and benign ascites: L . Buo, T. S. Karlsrud, H. T. 
Johansen & A. O. Aasen 117 
Glycation and oxidation of human low density lipoproteins reduces heparin binding and 
modifies charge: A. Gugliucci Creriche & A. J. C. Stahl 125 
An enzyme-linked immunosorbent assay for plasma-lactoferrin. Concentrations in 362 
healthy, adult blood donors: S. Antonsen, P. Wiggers, J. Dalhoj & O. Blaabjerg 133 
An E L I S A for elastase a!-protease inhibitor complexes in human plasma and serum: S. Anton-
sen & M. Wanscher 145 
Left ventricular end-diastolic dimensions measured at the P wave and Q wave during a 
randomized, double-blind one-year follow-up study comparing the effect of atenolol vs. 
hydrochlorothiazide + amiloride on blood pressure in men with mild to moderate 
hypertension: J. E. Otterstad, G. Froeland & J. Erikssen 155 
Assessment of glycaemic control in non insulin-dependent diabetes mellitus: S. Wettre, H. J. 
Arnqvist & H. von Schenck 163 
Luminol enhanced Fc-receptor dependent chemiluminescence from peripheral PMN cells. A 
methodological study: K. Bergström & B. Äsman 171 
Coagulation factors and lipid composition of the blood in treated and untreated hypertensive 
patients: S. H. J. Donders, F. A. Th. Lustermans & ./. W. J. van Wersch 179 
The effect of digoxin on the serum potassium concentration: M. Edner, P. Ponikowski &. 
T. Jogestrand 187 
Increased urinary loss of high density lipoproteins in albuminuric insulin-dependent diabetic 
patients: A. B. Haaber, M. Deckert, S. Stender & T. Jensen 91 
Continuous blood gas monitoring in haemodialysis using an electrode inserted in the extra-
corporeal dialysis circulation: G. Nielsen, C. Bredahl & C. Nielsen 197 
Erratum 
Are ethane and pentane evolution and thiobarbituric acid reactivity specific for lipid peroxi-
dation in erythrocyte membranes?: O. M. Pitkanen 201 
No. 3 
Review 
Cardiovascular and renal effects of atrial natriuretic factor: G. Christensen 203 
Original Articles 
Van Beaumont's formula is valid during haemodialysis. Spectrophotometric determination of 
body circulating haemoglobin: K. C. Rasmussen, R. Hansen, S. Fugelberg & N. Fogh-
Andersen 211 
Filtering clinically significant hypercalcaemia from non-significant hypercalcaemia at the 
laboratory level: A. Freiich, B. Friis Nielsen, K. Conradsen & P. McNair 215 
Proliferation and triglyceride synthesizing activities of fibroblast-like cells derived from epidi-
dymal and subcutaneous adipose tissuess of rats: H. Inadera, Y. Ishikawa, K. Shirai, Y. 
Saito & S. Yoshida 225 
Importance of the exercise programme for the assessment of functional capacity after myo-
cardial infarction: P. K. Ronnevik, J. E. Nordrehaug & G. Von der Lippe 231 
Ionophore A23187 reduces energy charge by enhanced ion pumping in suspended human 
erythrocytes: /. Engström, A. Waldenstrom & G. Ronquist 239 
Effects of ionophore gramicidin D on energy metabolism in human erythrocytes: /. 
Engström, A. Waldenstrom & G. Ronquist 247 
Performance of the Reflotron and Seralyzer on primary health care: G. Thue & S. Sandberg. 253 
Aspects of preanalytical variation of lactoferrin and elastase/aj-protease inhibitor complexes: 
S. Antonsen, N. Qvist & M. Wanscher 263 
Interactions of vitamins A and E and retinol-binding protein in healthy Swedish children — 
evidence of thresholds of essentiality and toxicity: P. Drott, S. Meurling & M. Gebre-
Medhin 275 
Protein S degredation in vitro by neutrophil elastase: /. Eckle, R. Seitz, R. Egbring, G. Kolb 
& K. Havemann 281 
Prognostic importance of plasma lioprotein-analyses in patients with unstable coronary 
artery disease: E. Swahn & H. Von Schenck 289 
Effects of platelets from men with risk factors for atherosclerosis on endothelial cell prolifera-
tion and prostacyclin production in vitro: P. Falke, I. Mattiasson & L . Stavenow 297 
Referees 
List of referees for 1992 305 
No. 4 
Original Articles 
Epinephrine induces /^-adrenergic desensitization and differentiation of HL-60 cells: B. E. 
Bang, J. Aarbakke & G. Sager 311 
An in vitro characterization of a silicone tonometer system for synchronous measurement of 
tissue oxygen- and carbon dioxide tension: P. N. Larsen, I. Pedersen & F. Moesgaard. . 317 
Urinary D-glucaric acid, a marker substance for microsomal enzyme induction. Methodologi-
cal aspects, responses to alcohol and findings in workers exposed to toluene: O. Sand-
stad, T. Osnes, V. Skar & M. Osnes 327 
The 'midband' lipoprotein is a coronary risk factor in Japanese patients with familial 
hypercholesterolemia: J. Tashiro, T. Nishide, M. Shinomiya, K. Shirai, Y. Saito, S. 
Yoshida, M. Yamashita, H. Ohshima & H. Murayama 335 
Superoxide release by primary-cultured human hepatic macrophages and peripheral mono-
cytes from patients with normal cirrhotic livers: Funaki, S. Arii, Y. Adachi, H. Higa-
shitsuji, J. Tanaka & T. Tobe 339 
Tumour necrosis factor-a can modulate the phenotype of aortic smooth muscle cells: 
N. Morisaki, Q.-P. Xu, T. Koshikawa, Y. Saito, S. Yoshida & S. Veda 347 
Effects of ovarian stimulation on blood pressure and plasma catecholamine levels: A. Tollan, 
P. 0ian, S. E. Kjeldsen, N. Holst & I. Eide 353 
Concentrations of pancreatic secretory trypsin inhibitor (PSTI), acute phase proteins, and 
neopterin in Crohn's disease. Comparison with clinical disease activity and endoscopical 
findings: L . Halme, K. von Smitten, S. Stenman, U. Turpeinen & U.-H. Stenman 359 
pH optimum of the reduction of dehydroascorbic acid by dithioerytritol: L . 0dum 367 
Ischaemia-reperfusion and toxic oxygen metabolites do not induce release of immunoreactive 
atrial natriuretic factor from isolated rat hearts: G. Valen, I. Lettrem, J. Sundsfjord & 
J. Vaage 373 
Reduction of infarct volume by thrombolysis with rt-PA in an embolic rat stroke model: 
K. Overgaard, T. Sereghy, G. Boy sen, H. Pedersen & N. H. Diemer 383 
Does glibenclamide influence the clearance of insulin and glucose uptake in patients with 
type 2 diabets mellitus?: E. Widen 395 
The relationship between early insulin release and glucose tolerance in healthy subjects: P. H. 
Groop, A. Melander & L . C. Groop 405 
Peripheral venous oxygen saturation during head-up tilt induced hypovolaemic shock in 
humans: P. Madsen, H. L . Olesen, M. Klokker & N. H. Secher 411 
The effect of low-dose supplementation with n-3 polyunsaturated fatty acids on some risk 
markers of coronary heart disease: H.-H. Lervang, E.B. Schmidt, J. Moller, N. Svane-
borg, K. Varming, P.H. Madsen & J. Dyer berg 417 
No. 5 
Invited Review 
Magnetic resonance imaging and spectroscopy of the human heart: J. Hartiala, H. Sakuma & 
C. B. Higgins 425 
Original Articles 
The diagnostic and prognostic value of serum bone Gla protein (osteocalcin) in patients with 
recurrent breast cancer: C. Kamby, C. Egsmose, G. Sole tor mos & P. Dombernowsky . . . 439 
Oxygen radicals stimulate thromboxane and prostacyclin synthesis and induce vasoconstric-
tion in pig lungs: J. Sanderud, K. Bj^ro & O. D. Saugstad 447 
Effectiveness of low-dose lovastatin combined with low-dose colestipol in moderate to severe 
primary hypercholesterolemia: S. Tons tad, L . Ose, C. Gorbitz, E. M. Harrison & H. J. 
de Koning Gans 457 
Homocysteine in frozen plasma samples. A short cut to establish hyperhomocysteinaemia as 
a risk factor for arteriosclerosis?: B. Israelsson, L . Brattström & H. Refsum 465 
Cyclosporine A monitoring in patients with renal, cardiac, and liver transplants: a compari-
son between fluorescence polarization immunoassay and two different RIA methods: S. 
Bergan, H. E. Rugstad, O. Stokke, 0. Bentdal, T. Froysaker & A. Bergan 471 
Unchanged noradrenaline reactivity and blood pressure after corrective surgery in primary 
hyperparathyroidism: B. Jespersen, A. Brock, P. Charles, H. Danielsen, S. S. Stensen & 
E. B. Pedersen 479 
Oligoclonal IgG in cerebrospinal fluid detected by isoelectric focusing using PhastSystem™: 
L.-O. Hansson, H. Link, L . Sandlund & R. Einarsson 487 
Studies on triglyceride metabolism: phosphatidate phosphohydrolase from guinea pig Harder-
ian gland: E. Humble & L . Berglund 493 
Erythrocyte deformability, endothelin levels, and renal function in cyclosporin-treated renal 
transplant recipients: effects of intervention with fish oil and corn oil: N. H. Schut, H. J. 
G. Bilo, C. Popp-Snijders, P. T. Goedhart & J. M. Wilmink 499 
Estimation of blood-glucose variability in patients with insulin-dependent diabetes mellitus: 
E. Moberg, M. Kollind, P.-E. Lins & U. Adamson 507 
Retinol and retinyl esters in rabbit bone marrow and blood leukocytes: B. Skrede, A. E. 
Olafsdottir, R. Blomhoff & K. R. Norum 515 
Ion effects in measurement of sodium and ionized calcium in direct potentiometry: F. Zoppi, 
E. Guagnellini & A. Manzoni 521 
Incomplete recovery of sodium determined in direct potentiometry in blood samples added 
with heparin salts: F. Zoppi, E. Guagnellini & A. Manzoni 529 
No. 6 
Original Articles 
Turnover and distribution of cathepsin G in the rat: P. Björk, A. Luts, F. Sundler & K. 
Ohlsson 539 
Disposal of atrial natriuretic factor ( A N F 9 9 _ 1 2 6 ) in patients with cirrhosis: effect of beta-
adrenergic blockade: F. Bendtsen, A. L . Gerbes & J. H. Henriksen 547 
Effects of psychological stress on plasma interleukins-1 beta and 6, C-reactive protein, 
tumour necrosis factor alpha, anti-diuretic hormone and serum Cortisol: B. Dugue, E. A. 
Leppänen, A. M. Teppo, F. Fyhrquist & R. Gräsbeck 555 
Evaluation of a new chromogenic substrate assay for the measurement of the prothrombin 
time: J. W. J. van Wersch 563 
Plasma immunoreactive Neuropeptide Y in congestive heart failure and during exercise: B. 
K. Madsen, D. Husum, R. Videbaek, K. H. Stokholm, L . Saelsen & N. J. Christensen... 569 
Diurnal blood pressure profile in patients with severe congestive heart failure: dippers 
and non-dippers: J. Kastrup, H. Wroblewski, J. Sindrup, H. Rolighed Christensen & 
N. Wiinberg 577 
Effect of cold pressor test and awareness of hypertension on platelet function in normoten-
sive and hypertensive women: H. H. Mundal, G. Nordby, K. Lande, K. Gjesdal, S. E. 
Kjeldsen & I. Os 585 
Water immersion and salt-sensitivity in essential hypertension: P. Coruzzi, L . Musiari, G. L . 
Mossini, R. Ceriati & A. Novarini 593 
Dose response dependency in regulation of acute PTH(l-84) release and suppression in 
normal humans: a citrate and calcium infusion study: P. Schwarz 601 
Normocalcaemic hyperparathyroidism after parathyroidectomy: a retrospective study: H. 
Mulder, J. Koster, W. H. L . Hackeng & H. van der Schaar 607 
Within-subject variation of elastase/a! protease inhibitor complexes and lactoferrin in 
plasma: S. Antonsen 611 
Protein profile in bronchoalveolar lavage fluid from patients with sarcoidosis and idio-
pathic pulmonary fibrosis as revealed by S D S - P A G E electrophoresis and Western blot 
analysis: M. Uebelhoer, B. Bewig, M. Oldigs, D. Nowak, H. Magnussen, W. Petermann & 
J.Barth 617 
Decrease of ischaemic-reperfusion related lung oedema by continuous ventilation and allo-
purinol in rat perfusion lung model: M. Okuda, K. Furuhashi, Y. Nakai & M. Muneyuki 625 
A clinical and biochemical study on tissue polypeptide antigen (TPA) in non-malignant hepa-
tic disorders: J. Collazos, J. Genollä & A. Ruibal 633 
The reference range for complexed a2-macroglobulin human plasma: development of a new 
enzyme linked-in immunosorbent assay ( E L I S A ) for quantitation of complexed a2-
macroglobulin: M. H. Jespersen, J. Jensen, L . H. Rasmussen, E. Ejlersen, J. Moller-
Petersen & H. U. Sperling-Peter sen 639 
Recommendation 
Establishing reference values from adults: recommendation on procedures for the preparation 
of individuals, collection of blood, and handling and storage of specimens: T. Alström, 
R. Gräsbeck, B. Lindblad, H. E. Solberg, P. Winkel & L . Viinikka 649 
No. 7 
Original Articles 
Determination of iron by the Ferrochem II: interference by tuberculostatics: M. E. Son Jose, 
A. Sarandeses, D. Alvarez, L . Vaides, B. Chomön & M. J. Del Rio 653 
Haemostatic activation in patients with head injury with and without simultaneous multiple 
trauma: J. V. Sorensen, H. P. Jensen, H. B. Rahr, L . C. Borris, M. R. Lassen, O. Fed-
ders, J. P. Haase & F. Knudsen 659 
A simplified method to determine galactose elimination capacity in patients with liver dis-
ease: M. Bergström, C. Söderman & L . S. Eriksson 667 
Cholecystokinin and somatostatin modulate the glucose-induced insulin secretion by different 
mechanisms in pancreatic islets: D. Malm, A. Glcever, B. Vonen & J. Florholmen 671 
Diagnostic performance and prognostic value of serum troponin T in suspected acute myo-
cardial infarction: J. Ravkilde, M. Herder, W. Gerhardt, L . Ljungdahl, T. Petterson, 
N. Try ding, B. H. Moller, A. Hamfelt, T. Graven, A. Asberg, M. Heiin, I. Penttilä & 
K. Thygesen 677 
Genetic carrier detection in Norwegian families with acute intermittent porphyria: E. Sagen, 
A. Lcegried, M. Anvret, G. Lundin, L . Lannfelt, L . Lilius, Y. Floderus & I. Romslo 687 
Diagnostic accuracy evaluation using R O C curve analysis: J. Huguet, M. J. Castineiras & 
X. Fuentes-Arderiu 693 
Increased activity of 5'nucleotidase in serum of patients with sickle cell anaemia: A. O. 
Mohamed, A. Jansson & G. Ronquist 701 
Diagnosis of urinary tract infection by urine microscopy using a disposable counting cham-
ber: M. Hiraoka, Y. Hida, S. Tuchida, H. Tsukahara, M. Yamashita, M. Kuroda & 
M. Sudo 705 
Rabbit lung macrophages stimulate platelets in vitro as observed by density-gradient centrifu-
gation and transmission electron microscopy: L . Jorgensen, G. J. Nilsen, D. W. 
Perry, ./. F. Mustard & R. L . Kinlough-Rathbone 711 
The cost of screening for hypercholesterolaemia—results from a clinical trial in Swedish 
primary health care: M. Johannesson, L . Borgquist, P. Nilsson-Ehle, B. Jönsson, T. 
Ekbom & L . Lindholm 725 
Increased lipolytic activity of sera from pre-eclamptic women due to the presence of a lyso-
phospholipase: M. J. Endresen, B. Lorentzen & T. Henriksen 733 
Pre-operative plasma tetranectin as a prognostic marker in ovarian cancer patients: C. K. 
Hogdall, E. V. S. Hogdall, U. Hording, I. Clemmensen, B. Norgaard-Pedersen & K. 
Toftager-Larsen 741 
Gender difference in red blood cell thiopurine methyltransferase activity: B. Klemetsdal, E. 
Wist & J. Aarbakke 747 
Modelling of serial carcinoembryonic antigen changes in colectoral cancer: / . Carl, S. M. 
Beutzen, B. Norgaard-Pedersen & O. Kronborg 751 
Total protein in common duct bile measured by acetonitrile precipitation and a micro 
bicinchoninic acid (BCA) method: T. Osnes, O. Sandstad, V. Skar, M. Osnes & P. Kier-
ulf 757 
Altered erythrocyte transmembrane transport of sodium and potassium in patients with con-
ventional or reservoir ileostomy: H. Brevinge, H. Herlitz & O. Jonsson 765 
No. 8 
Original Articles 
Efflux of cholesterol from cholesterol loaded macrophages by incubation with synthetic 
HDL-particles: / . Westman, C. Roobol, C. Heymans, L . A. Carlson & E. Wülfert 773 
Antigen-specific human T-cell colony formation in a liquid culture system: E. Keystone, L . 
Poplonski, K. M. Snow, C. Paige & R. G. Miller 783 
The effect of daily low-dose iron supplements in female blood donors with depleted iron 
stores: comparison with female non-donors: B. Borch-Iohnsen, R. Halvorsen, V. Sten-
berg, 0. Flesland & P. Mowinckel 789 
Thyroid hormones, procollagen III peptide, body composition and basal metabolic rate in 
euthyroid individuals: K. Stenlöf, L . Stöström, B. Fagerberg, E. Nyströ'm & G. Lindstedt 793 
Morphine and morphine/naloxone modification of glucose, glucagon and insulin levels in 
fasted and fed rats: O. Johansen, T. Tonnesen, T. Jensen, P. G. Burhol, R. Jorde & O. 
Reikeras 805 
Increased urinary polyamine excretion after starting a very low calorie diet: M. Uusitupa, 
M. Pöyhönen, H. Sarlund, M. Laakso, A. Kari, T. Helenius, L . Alakuijala & T. Eloranta 811 
Contributory roles of circulatory glucagon and growth hormone to increased renal haemo-
dynamics in type 1 (insulin-dependent) diabetes mellitus: K. Hoogenberg, R. P. F. 
Dullaart, N. J. M. Freiing, S. Meijer & W. J. Sluiter 821 
Estimated treatment responses in metastatic colorectal carcinoma based on longitudinal carci-
noembryonic antigen series: / . Carl, N. Brunsgaard, M. Kjaer & B. Norgaard-Pedersen . 829 
Comparison of three independent methods as estimates of platelet inhibition after a single 
dose of acetylsalicylic acid: K.-E. Karlberg, J. Chen, N. Egberg, J. Nowak & C. Sylven. . 835 
Concurrent neutral endopeptidase and A C E inhibition in experimental heart failure: renal 
and hormonal effects: K Helin 843 
Phosphofrucktokinase activity in human skeletal muscle: effects of euglycaemic hyperinsuli-
naemia and fasting: A. Katz & Z. Yan 853 
Effect of Captopril on the renal veno-arterial gradient of erythropoietin and oxygen in unilat-
eral renal artery disease: J. D. Jensen, H. Eiskjcer, B. Madsen, M. Egeblad, C. B. Nielsen 
& E. B. Pedersen 859 
Urinary albumin excretion in a population based sample of 1011 middle aged non-diabetic 
subjects: J. S. Jensen, B. Feldt-Rasmussen, K Borch-Johnsen, G. Jensen & The Copen-
hagen City Heart Study Group 867 
Infusion of E P A and D H A lipid emulsions: effects on heart lipids and tolerance to ischae-
mia-reperfusion in the isolated rat heart: J. Schjott, O.-L. Brekke, P. Jynge, K. S. Bjerve 
& T. Hamazaki 873 
Short Communication 
Hypouricaemia in a hospital population: M. Crook 883 
Indices 
Index of key-words 887 
Index of authors 890 
Scand J Clin Lab Invest 1993; 53: 547-554 
Disposal of atrial natriuretic factor (ANF 9 9 _ 1 2 6 ) 
in patients with cirrhosis: effect of 
beta-adrenergic blockade 
F . B E N D T S E N , * A . L . G E R B E S t & J . H . H E N R I K S E N f 
*Department of Medicine V (Hepatology), Ärhus Kommunehospital, University of Ärhus, 
Denmark, fDepartment of Clinical Physiology, Hvidovre Hospital, University of Copenhagen, 
Denmark and ^Department of Internal Medicine II , Klinikum Grosshadern, Ludwig Maximilians 
University, Munich, Germany 
Bendtsen F , Gerbes A L , Henriksen J H . Disposal of atrial natriuretic factor 
( A N F 9 9 _ 1 2 6 ) in patients with cirrhosis: effect of beta-adrenergic blockade. 
Scand J Clin Lab Invest 1993; 53: 547-554. 
To test a possible effect of blood flow change on disposal of atrial natriuretic 
factor: A N F 9 9 _ ! 2 6 (ANF), we determined renal, azygos, hepatic and cubital 
venous, and arterial plasma concentrations of A N F in 18 patients with cirrho-
sis before and after ingestion of propranolol 80 mg. Arterial A N F was similar 
to that of controls (9.4 vs. 10.9pm.oir 1, NS) and was positively correlated to 
cardiac output (r = 0.49, p < 0.02) and to right atrial pressure (r = 0.44, 
p < 0.01). All the vascular beds examined extracted A N F significantly. The 
renal (n = 17), hepato-enteric (n = 16), and splanchnic superior collateral (azy-
gos) beds (n = 13) had significantly higher extraction ratios (0.34-0.39) than 
that observed in the cubital vein (0.24, n = 15, p < 0.05). Arterial A N F showed 
no significant change (9.6-11.0 pmol l - 1 , NS) after reduction of cardiac output 
(—25%, p < 0.001) by propranolol. Only insignificant changes in A N F extrac-
tion and a small decrease in azygos and hepato-enteric clearance occurred during 
beta-adrenergic blockade. Our results show a substantial extraction of A N F in 
the kidney, in the splanchnic bed drained through superior porto-
systemic collaterals, and in the hepato-enteric bed. Only minor effects on A N F 
extraction were observed after reduction of the blood flow with propranolol. 
Key words: atrial natriuretic factor (ANF); beta-adrenergic blockade; cirrhosis; 
extraction; propranolol 
Jens H. Henriksen, MD, Department of Clinical Physiology, 239, Hvidovre Hos-
pital, DK-2650 Hvidovre, Denmark 
Atrial natriuretic factor: A N F 9 9 _ ] 2 6 (ANF) is a 
circulating hormone with natriuretic and vasodi-
lating effects [1, 2]. In patients with cirrhosis, dif-
ferent levels of plasma A N F has been reported: 
from below normal to highly elevated values 
[3-9]. However, the circulating level of A N F is 
not only governed by release, but by the dynamic 
equilibrium between release and disposal, and 
recent reports document major extraction (15-
60%) of this peptide in various tissues [5, 10-13]. 
Treatment with beta-adrenergic blockers is 
common in patients with cirrhosis [14]. Propran-
547 
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olol reduces cardiac output and hepatic blood 
flow in most of the patients [15]. As the overall 
clearance of a high extraction substance may 
be flow dependent, it could be anticipated that 
a reduction in blood flow would result in 
decreased disposal and elevated circulating 
levels. However, the effect of a change in blood 
flow on disposal and extraction of A N F has 
hitherto not been investigated in patients with 
cirrhosis. 
Therefore, the present study was undertaken 
to determine circulating A N F in patients with 
cirrhosis before and during beta-adrenergic 
blockade. We measured the concentration of 
A N F in arterial, renal, azygos, hepatic, and cubi-
tal venous plasma before and during propranolol 
ingestion in order to examine whether a decrease 
in blood flow affects the disposal of A N F . 
P A T I E N T S A N D M E T H O D S 
The study comprised a total of 18 patients (2 
women, 16 men) with cirrhosis, as verified by 
biopsy, aetiology for all was alcohol. The age 
range was 30-69 years, mean 58 years. All the 
patients were considered to be in a stable condi-
tion and had abstained from alcohol for at least 
one week. There were no signs of current con-
sumption of alcohol or of withdrawal symp-
toms. Endoscopy revealed oesophageal varices 
in all patients. None had experienced gastro-
intestinal bleeding or hepatic encephalopathy 
above grade I. Six patients were in Child-
Turcotte Class A, 7 in Class B, and 5 in Class C. 
Fluid retention and ascites were present in 10 
patients. Patients without fluid retention were 
not restricted as to diet, whereas those with 
ascites were put on a sodium diet of 40 mmol 
day - 1 . Ten patients received diuretics (spirono-
lactone lOOmgday - 1 and additionally bumeta-
nide l -8mgday _ 1 ) . The biochemical data are 
summarized in Table I. Six patients, described 
in [16] with disorders of minor degree (one inter-
costal neuralgia, one dermatomyositis, one 
chronic hepatitis, two irritable bowel syndrome, 
one post cholecystectomy pain) and unrestricted 
diet served as controls. Their age range was 50-
68 years, mean 62 years. 
Patients and controls consented to participate 
in the investigation after receiving a thorough 
explanation verbally and in writing. The study 
was approved by the Ethics Committee for 
Medical Research in Copenhagen. No complica-
tions or side-effects were encountered during the 
investigative procedures. 
Catheterization 
Patients and controls were studied in the 
morning after an overnight fast. Catheteriza-
tion was performed under local anaesthesia 
with the subject lying supine. Azygos venous 
blood was collected from the femoral route 
with either a double thermistor coronary sinus 
catheter (Webster Laboratories, Altadena, C A ) 
or a Swan-Ganz catheter as described elsewhere 
[17]. Hepatic and right renal venous blood was 
collected with a Cournand 7 F catheter as 
described elsewhere [18]. A small indwelling 
polyethylene catheter was introduced to the 
femoral artery and cubital vein by the Seldinger 
technique. 
The azygos venous blood flow was measured 
by the continuous infusion thermodilution tech-
nique [16, 17], and the hepatic blood flow by the 
indocyanine green constant infusion technique 
[19]. Arterial and right atrial pressures were 
measured with a capacitance transducer (Simon-
sen & Weel, Copenhagen). The mid-axillary line 
was taken as zero pressure reference. Heart rate 
was recorded by E C G . 
Protocol 
Blood samples for determination of endogen-
ous A N F in plasma were taken simultaneously 
from artery/azygos vein, artery/hepatic vein, 
artery/right renal vein, and artery/cubital vein. 
Blood samples were collected and the blood 
flow and pressures were measured to obtain 
baseline values without medication and pro-
cedures were repeated 90 min after oral adminis-
tration of propranolol 80 mg [20]. 
Analysis of endogenouss human alpha-atrial 
natriuretc factor 
After discharging the catheter dead space, 
5 ml of blood was collected on ice into test tubes 
containing aprotinine 2500 K I U and heparin 
250 I U . The samples were immediately centri-
fuged at 4 °C and the plasma was stored at 
—25° C until assayed. Plasma was extracted 
and A N F was determined by radio-immuno-
assay as described elsewhere [21, 22]. Intra-
Table I . Laboratory data of 18 patients with cirrhosis. 
S-aspartate 
amino- S-alkaline Factor Plasma 
Haemoglobin S-bilirubin transferase phosphatase 2, 7, 10 S-Na + S-K + S-creatinine S-albumin volume 
( m m o i r 1 ) ( ^ m o i r 1 ) ( U P 1 ) ( U P 1 ) Index (mmol l " 1 ) ( m m o i r 1 ) ( / x m o i r 1 ) Ornioir1) (ml kg" 1 ) 
Cirrhosis 
Mean 8.3 33 67 384 0.70 137 3.9 80 492 56 
(range) (6.9-9.8) (7-115) (29-150) (211-807) (0.29-1.51) (130-144) (3.4-5.2) (55-135) (288-666) (41-79) 
Reference F: 7.1-9.9 2-17 10-40 50-275 0.7-1.3 136-147 3.5-5.0 49-121 540-800 35-65 
interval M : 8.1-10.9 
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( d y n s c m - 5 ) 
Cardiac 
output 








( l m i n " ' ) 
Cirrhosis (n) (18) (18) (18) (17) (17) (18) (9) 
Before 
propranolol 76 ± 2.6 b 2.6 ± 0.54 84 ± 3.3a 1020 ± 68 c 3.70 ± 0.23a 1.16 ± 0.07 0.98 ± 0.19 
After 
propranolol 62 ± 2.0* 3.8 ± 0.69t 79 ± 2.6 1275 ± 80f 2.82 ± 0.15t 0.92 ± 0.08f 0.71 ± 0 . 0 7 * 
Controls 
( n = 1 6 ) 68 ± 2.3 3.5 ± 0.68 95 ± 3.3 1490 ± 128 2.99 ± 0 . 1 8 - -
Mean ± SEM 
Compared to value before propranolol: * p < 0.025; f p < 0.005 
Compared to control value: a p < 0.05; b p < 0.02; c p < 0.01. 
assay and inter-assay coefficients of variation 
were below 10% and 15%, respectively. The de-
tection limit was 0.5pmoll~ l. 
Calculations and statistical evaluation 
Extraction ratio (E). This was assessed as 
E = ( C a - C v ) / C a , where C a and C v are the 
plasma concentrations of A N F in the artery 
and organ vein, respectively. 
Clearance (CI) . Clearance in azygos and 
hepato-enteric beds was assessed as CI = 
F • (1 — Hct) • E , where F is the azygos and 
hepatic blood flow, and Hct is the haematocrit 
fraction. 
Paired and grouped differences were com-
pared by Student's paired and unpaired two-
sided /-tests, and the Bonferroni correction was 
applied in multiple group comparison. Corre-
pmol I"1 
Artery Hepatic Renal Periphe- Azygos 
n=18 vein vein rial vein vein 
n=15 n=17 n=1§ n=1l 
Fig. 1. Plasma A N F in different vascular beds in 
patients with cirrhosis before Q and after propranolol 
ingestion • . Mean + SEM. 
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Cardiac output (I min"') 
Fig. 2. Relation between cardiac output and arterial plasma A N F in 18 patients with cirrhosis (r = 0,49, p < 0.02). 
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Right atrial pressure (mmHg) 
10 
Fig. 3. Relation between right atrial pressure and arterial A N F in 18 patients with cirrhosis, before O and after A 
propranolol ingestion (r = 0.44, p < 0.01). 
lations were analysed by the Pearsson corre-
lation coefficient, p < 0.05 was considered signif-
icant. Values are given as mean ± S E M . 
R E S U L T S 
Table II summarizes the haemodynamic results. 















reduction was observed in the heart rate, cardiac 
output, and hepatic and azygos blood flow, 
whereas a slight, but significant, increase was 
observed in the right atrial pressure. 
The mean arterial concentration of A N F in 
the patients was similar to that of the controls 
(9.4 vs. 10.9 ± 3 . 1 pmol l" 1 NS). There was 
only an insignificant increase after propranolol 
ingestion (9.4 to 11.0 pmol r 1 NS), and no sig-
nificant change was observed in A N F from the 
venous beds (see Fig. 1). Arterial A N F in the 
cirrhotic patients was positively correlated to 
cardiac output (r = 0.49, p < 0.02, Fig. 2) and 
to the right atrial pressure (r = 0.44, p < 0.01, 
Fig. 3). No relation to the heart rate could be 
demonstrated. 
All the vascular beds examined showed a sig-











z < 200 -
Fig. 4. Arterio-venous extraction ratios in different 
vascular areas in patients with cirrhosis before O 
and after propranolol ingestion • . 
Fig. 5. Azygos and hepato-enteric clearances of A N F 
in patients with cirrhosis before ED and after proprano-
lol ingestion • . 
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(0.39 ± 0.06), hepato-enteric (0.34 ± 0.06), and 
azygos bed (0.38 ± 0.07) extraction ratios were 
significantly higher than that for the cubital 
vein (0.24 ± 0 . 0 8 , p < 0.05). No significant 
changes in extraction ratios were observed dur-
ing beta-adrenergic blockade (Fig. 4). A non-sig-
nificant change in azygos and hepato-enteric 
clearance of A N F was seen after propranolol 
ingestion (Fig. 5). 
D I S C U S S I O N 
The arterio-venous extraction technique is a 
well-established method of obtaining informa-
tion on regional disposal of a variety of bioac-
tive substances [10, 12, 18, 23, 24]. The present 
study shows substantial extraction of A N F in 
the azygos, hepato-enteric, and renal venous 
beds. Removal of A N F was smaller in the fore-
arm circulation. 
The high extraction of A N F in renal, hepatic, 
and azygos venous plasma probably reflects the 
presence of peptidases and specific degradation 
receptors [13]. It has been demonstrated that 
A N F is rapidly hydrolysed by endopeptidase 
24.11, a membrane-bound metallo-peptidase that 
hydrolyses bonds involving the amino-group of 
hydrophobic amino acid residues (i.e. cysphe) 
[25, 26]. Two types of receptors with specific 
affinity for A N F have been described: B and C 
receptors [27, 28, 29]. The B receptor appears 
to mediate the biological response to A N F 
through cGMP as second messenger [27, 30]. 
Since no second messenger has been unequivo-
cally identified when A N F binds to the C recep-
tor, Fuller and co-workers [31] suggest that it is 
a 'silent' clearance receptor with internalization 
of the peptide and subsequent degradation within 
lysosomes as the outcome [31]. The relative abun-
dance of the two receptors varies widely in the dif-
ferent tissues. Endopeptidase 24.11 and A N F 
receptors have been identified in most vascular 
endothelial cells, including those of the hepato-
splanchnic bed [32-36]. The high A N F extrac-
tion ratio in azygos plasma, as found in the pres-
ent study, is similar to extractions described in 
most other tissues [9-12]. Therefore, our find-
ings may suggest that the degradation of A N F 
in blood drained through the azygos venous 
bed is mediated by the same mechanism as 
those described for other tissues, i.e. related to 
vascular endothelial cells. 
Propranolol produced a substantial reduction 
in the blood flow rates. None the less, extraction 
ratios and clearances exhibited only small 
changes, which indicates that the disposal of 
A N F only manifests a minor dependence on a 
reduction in blood flow. No previous report 
has addressed this question. Peripheral plasma 
A N F does not change during beta-adrenergic 
blockade in normal humans [37, 38]. 
Modulation of A N F kinetics by adrenergic 
agonists is controversial [39, 40]. Propranolol, 
in itself, might alter the kinetics of A N F . How-
ever, this point of view was not supported by a 
recent report by Keller et al. [41], who did not 
find any change in plasma A N F during infusion 
of beta-adrenergic agonists or antagonists to 
normal humans. In the present study, A N F 
was directly correlated to right atrial pressure, 
when the values, before and after propranolol 
ingestion were compared. This is probably 
because of the small, but significant, increase in 
right atrial pressure during beta-adenergic 
blockade [2, 38], and may thus be a conse-
quence of a somewhat augmented release of 
A N F rather than of a change in disposal. A N F 
was directly correlated to cardiac otuput, a find-
ing that probably reflects a change in the release 
of A N F which could be caused by the hyper-
dynamic circulation in the presence of cirrho-
sis, rather than to a change in disposal [41, 42]. 
To summarize, our results in patients with cir-
rhosis show a substantial extraction of A N F in 
the kidney, in the splanchnic bed drained 
through superior porto-systemic collaterals, 
and in the hepato-intestinal bed. Only minor 
effects on A N F extraction were observed after 
reduction of the blood flow with propranolol. 
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